<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if IE ]> <html class="no-js IE"> <![endif]-->
<!--[if IE ]> <html class="no-js IE"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js"> <!--<![endif]-->
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <title></title>
        <meta name="description" content="">
        <meta name="viewport" content="width=device-width, initial-scale=1">
        <link rel="stylesheet" href="css/styles.css">
        <link rel="stylesheet" href="css/customStyles.css">
    </head>
    <body>
        <div id="header">
            <div class="header mobileYes center">
                <a href="index.html"><img src="images/agilvaxHeaderLogo.png" alt="Agilvax" title="Agilvax" width="135"></a>
            </div>

            <div class="navigation">
                    <div class="mobileNavToggle">Menu</div>
                    <div class="navigationBar">
                        <ul class="nav navLeft">
                        </ul><!-- /nav -->
                        <ul class="nav navRight">
                        </ul><!-- /nav -->
                    </div><!-- /navigationBar -->
            </div><!-- /navigation -->
        </div><!-- #header -->

        <div class="pageTitle">
            <div class="containerNarrow">
                <h1 class="slideInBT">THE AGILVAX VLP PLATFORM</h1>
            </div>
        </div><!-- /pageTitle -->
        <div class="mainContent">
            <div class="container techPlatCircles">
                <div class="connector"></div><!-- /connector -->
                <div class="oneThird breakColMobile">
                    <div class="circle">
                        <img src="images/techPlatformClonnedGenes.jpg" title="Cloned Genes" alt="Cloned Genes">
                    </div>
                    <p class="tpDescription">1. Cloned genes: library or specific  antigens + VLP</p>
                </div><!-- /oneThird breakColMobile -->
                <div class="oneThird breakColMobile">
                    <div class="circle">
                        <img src="images/techPlatformBacterialBasedManufacturing.jpg" title="Bacterial Based Manufacturing" alt="Bacterial Based Manufacturing">
                    </div>
                    <p class="tpDescription">2. Bacterial based manufacturing</p>
                </div><!-- /oneThird breakColMobile -->
                <div class="oneThird breakColMobile gridLast">
                    <div class="circle">
                        <img src="images/techPlatformVLPCandidate.jpg" title="VLP Candidate" alt="VLP Candidate">
                    </div>
                    <p class="tpDescription">3. VLP vaccine candidate</p>
                </div><!-- /oneThird breakColMobile gridLast -->
            </div><!-- /container -->
            <div class="containerNarrow">
                <hr class="halfLightBlue">
                <h2>Agilvax’s technology has two important features that, until now, were not available in a single platform.</h2>
                <p><b>First</b>, the platform ensures high immunogenicity by displaying foreign peptides as dense repetitive arrays on the surface of a VLP. This results in vigorous immune responses to foreign antigens, as well as the ability to overcome immune tolerance and induces antibodies against self-antigens.</p>
                <p><b>Second</b>, the platform has the ability to recover and amplify affinity-selected sequences from complex random libraries, in a process analogous to phage display. The combination of these two features in a single platform facilitates rapid identification and development of novel immunotherapies and vaccines. As an additional advantage, this system does not require the use of eggs or mammalian cell culture for vaccine production and can therefore produce immunotherapies and vaccines in as little as two weeks, compared to the 20–24 weeks or more that traditional vaccine production methods often require.</p>
                <h2>Agilvax Propriety VLP Platform Highlights</h2>
                <ul>
                    <li>Ensures high immunogenicity by displaying foreign peptides as dense repetitive arrays on the surface of a VLP. This results in vigorous immune responses to foreign antigens, the ability to overcome immune tolerance, and induces antibodies against self-antigens.</li>
                    <li>Enables the recovery and amplification of affinity-selected sequences from complex random libraries, in a process analogous to phage display. The combination of these two features in a single platform facilitates rapid identification and development of novel vaccines.</li>
                    <li>Offers a wider safety margin by focusing on specific peptide antigens.</li>
                    <li>Offers low cost of goods (by virtue of being bacteriophage based) and avoids cold chain requirements, which is a significant advantages in price sensitive markets.</li>
                </ul>

            </div><!-- /containerNarrow -->
        </div><!-- /MainContent -->
       


        <div id="footer">
        </div><!-- /footer -->

        <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
        <script src="http://ajax.googleapis.com/ajax/libs/jqueryui/1.10.4/jquery-ui.min.js"></script>
        <script src="js/modernizr-2.6.2.min.js"></script>
        <script src="js/plugins.js"></script>

        <!-- LoadIncludes -->
        <script>
            $( ".navLeft" ).load( "includes/nav.html" );
            $( ".navRight" ).load( "includes/navRight.html" );
            $( "#footer" ).load( "includes/footer.html" );
        </script>
        <script src="js/main.js"></script>

    </body>
</html>
